Drug Search Results
Using advanced filters...
Advanced Search [+]

Fluciclatide

Alternative Names: fluciclatide
Latest Update: 2019-03-13
Latest Update Note: Clinical Trial Update

Product Description

Tracer for positron emission tomography / computed tomography (PET/CT) scans (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02193672)

Mechanisms of Action: Imaging Agent

Novel Mechanism: No

Modality: Diagnostic Agent

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GE Healthcare
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Adenocarcinoma|Colorectal Cancer|Pancreatic Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

18F-Fluciclatide tumor imaging

P2

Active, not recruiting

Colorectal Cancer|Pancreatic Cancer|Adenocarcinoma

2020-03-21

Recent News Events

Date

Type

Title